Background: Normosmic congenital hypogonadotropic hypogonadism (ncHH) is caused by the deficient production, secretion, or action of gonadotropin-releasing hormone (GnRH). Its typical clinical manifestation is delayed puberty and azoospermia. Homozygous and compound heterozygous mutations in the GNRHR gene (4q13.2) are the most frequent genetic causes of ncHH. Objectives: (i) Characterization at the molecular level (genetic origin and functional effect) of a unique homozygous mutation (p.Gly99Glu) in a ncHH man; (ii) to provide a comprehensive catalog of GNRHR mutations with genotype-phenotype correlation and comparison of in vitro studies vs. in silico prediction tools. Material and Methods: A ncHH man and his parents, in whom we performed the following: (i) Sanger sequencing, qPCR of the GNRHR gene; (ii) chromosome 4 SNP array; and (iii) competition binding assay and inositol phosphate signaling assay. PubMed and Human Genome Mutation Database (HGMD) search for GNRHR mutations. Bioinformatic analysis of 55 reported variants. Results: qPCR showed two GNRHR copies in the index case. SNP array revealed the inheritance of two homologous chromosomes 4 from the mother (maternal heterodisomy; hUPD) with two loss of heterozygosity regions, one of them containing the mutated gene (maternal isodisomy; iUPD). Functional studies for the p.Gly99Glu mutation demonstrated a right-shifted GnRH-stimulated signaling response. Bioinformatic tools show that commonly used in silico tools are poor predictors of the function of ncHH-associated GNRHR variants. Discussion: Functional analysis of the p.Gly99Glu mutation is consistent with severely decreased GnRH binding affinity (a severe partial loss-of-function mutation). Complete LOF variants are associated with severe and severe/moderate phenotype, whereas partial LOF variants show wide range of clinical manifestations. Conclusion: This is the first ncHH patient carrying a novel causative missense mutation of GNRHR with proven 'severe pLOF' due to maternal hUPD/iUPD of chromosome 4. Our literature review shows that functional studies remain essential both for diagnostic and potential therapeutic purposes.
INTRODUCTION
Gonadotropin-releasing hormone (GnRH) stimulates gonadotropins (FSH and LH) which are crucial for both reproductive and endocrine function of the testis. A deficit in LH and FSH secretion might be caused by congenital or acquired factors and these can be related to a primary lesion in the pituitary gland or secondary to insufficient hypothalamic GnRH production or action (Boehm et al., 2015; Krausz et al., 2018) . This pathological condition is referred as hypogonadotropic hypogonadism, and its clinical manifestation depends on the timing of onset of the disease. Among acquired hypogonadotropic hypogonadism, tumors in the central nervous system (CNS), empty sella, and chronic diseases such as hemochromatosis, sarcoidosis, and histiocytosis are the most frequent pathologies. Congenital hypogonadotropic hypogonadism is a rare genetic form of hypogonadism with a higher prevalence in male subjects (1 : 8000). It typically manifests with absent or delayed puberty, but the phenotypic presentation of this disease and its genetic background are highly heterogeneous (Krausz et al., 2018) . The first gene defect found to be responsible for isolated normosmic congenital hypogonadotropic hypogonadism (ncHH) was described in the GNRHR (de Roux et al., 1997) . The human GNRHR gene spans 18.7 kb of genomic sequence on the long arm of chromosome 4 (4q13.2) and it is expressed in pituitary gonadotropes. The GnRH-R is a member of the GPCR family, which consists of seven-transmembrane domains (TMDs) connected to each other with extra/intracellular loops (ECL/ICL), but notably it lacks a large intracellular cytoplasmic tail (Millar et al., 2004) . Homozygous and compound heterozygous mutations in the GNRHR gene are the most frequent genetic causes of ncHH (Francou et al., 2016) .
To date, 55 natural loss-of-function GNRHR mutations (SNVs and frameshift) have been reported in the literature (Table S4) . Almost all affected patients harbor homozygous or compound heterozygous rare variants; hence, the transmission of this genetic form is autosomal recessive (Maione et al., 2018) . Given the negative effect of GNRHR mutations on reproduction, the large majority of the mutations are private and non-recurrent. Nevertheless, three hot spot mutations are known in this gene (Gln106Arg, Arg139His, Arg262Gln) with the highest minor allele frequency (MAF) of 0.004 for the Gln106Arg (http://exac.broadin stitute.org/). These three mutations are founder mutations, suggesting a hypothetical selective advantage for heterozygote carriers (Choi et al., 2015) . The Gln106Arg and Arg262Gln mutations account for approximately half of all reported mutant alleles (Kim et al., 2010) . In case of compound heterozygosity, one allele frequently carries either Gln106Arg or Arg262Gln. The three hot spot mutations may also be homozygous in patients with unrelated parents, whereas rare homozygous mutations are typically found in consanguineous families. In non-consanguineous instances, homozygosity for a rare mutation is exceptional and implies either the deletion of the wild-type allele or uniparental isodisomy originating from a heterozygous carrier parent.
Uniparental disomy (UPD), a non-traditional Mendelian inheritance pattern, refers to a situation where an individual has inherited two copies of a specific chromosome (or part of it) from a single parent. The inheritance of a pair of chromosome homologs from a parent is defined as uniparental heterodisomy (hUPD), whereas the inheritance of two identical copies of a single chromosome homolog from a parent is defined as uniparental isodisomy (iUPD) (Engel, 1993) . This phenomenon has been described for almost all chromosomes with a relatively high frequency for chromosomes 6, 7, 11, 14, 15, and 16 (Liehr, 2014) .
In this article, we present the first ncHH case due to a novel homozygous GNRHR mutation related to UPD and its functional characterization. In addition, we provide a comprehensive literature review of all published GNRHR mutations, with special focus on variants with functional effects.
MATERIALS AND METHODS

Subjects
• A 20-year-old Caucasian male with high school diploma was admitted to our endocrinology department for delayed puberty. Physical examination revealed the presence of eunuchoid body shape with bilateral cryptorchidism and genital infantilism (Tanner stage 1; see also Table 1) . Height was at the 10th percentile, weight at the 50th percentile according to the national derived growth charts (https://www.cdc.gov/ growthcharts/data/set2/chart-07.pdf). No other syndromic clinical features were observed. Pelvic magnetic resonance imaging documented the presence of both testes in the inguinal canal at internal ring level (Fig. 1) The diagnostic workup included: (i) hormonal evaluation; (ii) abdominal and hypothalamus/pituitary magnetic resonance imaging (MRI); (iii) Utrecht test for sense of smell; (iv) radial bone scan; and (v) genetic testing. Routine biochemical examinations were all within the normal range. The baseline hormonal results are provided in Table 1 . Normal adrenal and thyroid axes and IGF-1 levels were documented. Both gonadotropins were undetectable, whereas total testosterone was 1.3 nM. The patient underwent a dynamic GnRH stimulation test, which documented an absence of both LH and FSH response (data not shown). Conversely, a growth hormone-releasing hormone + arginine test was normal (data not shown). Pituitary MRI documented partial empty sella. Abdominal MRI showed bilateral inguinal retained testes of about 2 mL. The Utrecht test confirmed the presence of normal sense of smell. The radial bone scan documented a bone age of 17 years. The karyotype was normal and was followed by molecular genetic analyses.
• Mother and father of the proband presented uneventful medical history and both of them underwent with spontaneous puberty (mother's menarche at age of 13 years, father puberty around the age of 14 years). Their height is reported in Table 1 , and it is of note that the mother height corresponds to the 90th percentile.
Sequencing analysis
Genomic DNA was extracted from EDTA-preserved blood using the salting-out method. Concentration and purity of DNA were measured with NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). The primers (Table S1) were designed with a bioinformatics tool (Primer-BLAST: National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA) using sequences for GNRHR gene (NCBI Reference Sequence: NG_009293.1). All exons, exon-intron boundaries, and the promoter region were covered. The Polymerase Chain Reaction (PCR) was performed and followed by the Sanger sequencing. Sanger sequencing was performed using the BigDye Terminator v3.1 sequencing kit and an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The mutation was confirmed by bidirectional sequencing. The pathogenic prediction for missense variation was realized using PolyPhen-2 (www.genetics.bwh.harvard.edu) SIFT (www.sift.jcvi.org) and MutationTaster (www.mutationtaster.org).
Microsatellite marker analysis
Six microsatellite loci located on six chromosome were investigated (Table S2 ) using genomic DNA from peripheral blood belonging to proband and his parents. The selected loci consisted of five dinucleotide tandem repeats (D6S436, D6S465, D6S1714, 5'AR, and D6S295) and one tetranucleotide tandem repeat (D6S1344).
Quantitative-PCR
We applied qPCR to identify deletion involving the entire GNRHR gene or part of it by designing a SYBR â Green assay based on the amplification of the exon 1 region including the codon 99 (Table S3 ).
High-density Single Nucleotide Polymorphism (SNP) genotyping array analysis Array genotyping was performed using the Affymetrix CytoScan 750K SNP array (Affymetrix Inc., Santa Clara, CA, USA). Briefly, array hybridizations were performed according to manufacturer's instructions. Following hybridization, the arrays were scanned on the GeneChip Scanner 3000 7G (Affymetrix Inc.). Data analysis was performed using the Chromosome Analysis Suite 3.1., Excel, and Galaxy.
Literature search and bioinformatics analysis of GNRHR mutations
• A comprehensive literature review was performed through the consultation of (i) the PubMed database, using the keywords 'GNRHR'; 'GNRHR and hypogonadotropic hypogonadism'; 'GNRHR and mutations'. Articles related to GNRHR gene variants in ncHH patients were manually selected for further analysis; (ii) the professional version of Human Gene Mutation Database (HGMD â ), available via subscription from QIAGEN (https://www.qiagenbioinformatics.com/).
• Bioinformatic analysis of the 27 variants with functional studies, based on in silico prediction tools (SIFT www.sift.jcvi.org, PolyPhen-2 www.genetics.bwh.harvard.edu, and Mutation Taster www.mutationtaster.org).
RESULTS
Molecular genetic analyses A novel homozygous rare variant, c.296G>A; p.Gly99Glu, was detected in exon 1 of the gene affecting the TMD2-ECL1 junction of the protein ( Fig. 2A) , and it was predicted as disease causing by in silico prediction tools (SIFT, Polyphen-2, MutationTaster). DNA analysis of the parents showed that the patient's mother was a heterozygous carrier of the same variant, whereas the father was wild type at this locus (Fig. 2B ). In addition, the father's DNA showed a rare heterozygous missense variant (c.436C>T; p.Pro146Ser), which was absent in our patient.
In order to unravel the origin of the rare homozygous mutation in the absence of the mutant allele in the father's genome, a series of molecular genetic analyses was performed (see above). First, a test using multiple single tandem repeat markers on chromosome 6 confirmed paternity. At this point, two potential scenarios were predicted for the proband's genotype: (i) the loss of the paternal GNRHR gene (deletion); (ii) the inheritance of a defective copy of the GNRHR gene in a homozygous state because of the occurrence of maternal iUPD of the entire chromosome 4 or of the DNA segment containing the mutated gene.
The first hypothesis was excluded following GNRHR gene dosage through qPCR, which revealed two copies of the gene. The second scenario was addressed by performing high-density single nucleotide polymorphism (SNP) genotyping array analysis (Affymetrix CytoScan 750KSNP array) (Fig. 3A) . SNP array analysis revealed two homozygous regions from band 4q12 to 4q21.21 and band 4q33 to 4q35.2, encompassing approximately 24 and 20 Mb, respectively. The parental SNP genotyping data for these regions showed the occurrence of maternal isodisomy, as only a single maternal allele was inherited by the patient. Comparison of the patient and parental SNP genotypes across the remaining part of chromosome 4 was consistent with maternal heterodisomy with no evidence of a paternal contribution on this chromosome. These results indicate that the patient inherited the pathogenic GNRHR variant in a homozygous state because of the occurrence of maternal iUPD of chromosome 4 at the GNRHR locus (Fig. 3B ).
Imprinted genes on chromosome 4
Although there were no abnormal clinical features present in the proband besides ncHH and short stature, we investigated if critical maternally imprinted genes were located on chromosome 4 through in silico analysis (http://www.geneimprint.com/ site/home). Only one gene, NAP1L5 (alias DMRL) which maps to 4q22.1, has been reported to be imprinted and to have monoallelic paternal expression (Smith et al., 2003; Wood et al., 2007) .
Functional studies of the p.Gly99Glu variant GnRH-R
Cos7 cells transfected with the wild-type GnRH-R showed significant binding of the radiolabeled high-affinity GnRH ago-
]-GnRH, which was inhibited by GnRH with high affinity (IC 50 , 5.77 AE 2.57 nM, Fig. 4A ). Cells transfected with the wild-type receptor with an appended carboxyterminal tail showed total radioligand binding that was 569.3 AE 197.5% wild-type binding, consistent with previous reports of increased GnRH receptor protein expression (Flanagan et al., 2000) . Cells transfected with the p.Gly99Glu mutant GnRH-R showed no measurable radioligand binding (Fig. 4A) . Appending a carboxy-terminal tail to the p.Gly99Glu mutant receptor did not enhance radioligand binding (Fig. 4A ), suggesting that any increased expression was not sufficient to allow binding of radioligand at the low concentration (~0.1 nM) used in competition binding assays. GnRH stimulated inositol phosphate (IP) production with high potency in cells transfected with the wild-type GnRH-R (Fig. 4B ). GnRH also stimulated IP production in cells transfected with the p.Gly99Glu mutant GnRH-R (Fig. 4B) , showing that the mutant receptor protein was expressed. However, GnRH potency was three orders of magnitude lower (EC 50 , 899.3 AE 324.3 nM) in cells expressing the mutant receptor (Fig. 4B ). Appending the carboxy-terminal tail to the p.Gly99Glu mutant GnRH-R had small Figure 3 (A) Results from the SNP array of our ncHH proband are consistent with normal copy number for chromosome 4 and demonstrate two regions (boxed regions) of loss of heterozygosity (LOH) spanning the long arm of chromosome 4. The GNRHR gene is located at 4q13.2, within the region of LOH1. (B) Explanatory diagram of the mode of transmission of the homozygous mutation (p.Gly99Glu) in the proband (shown by the arrow). The two rectangles represent both homologues of chromosome 4: The black one is the maternal allele carrying the novel p.Gly99Glu mutation, the one with dots is the wild-type maternal allele, the white one is the wild-type paternal allele, and the striped one is the paternal allele carrying the p.Pro146Ser mutation. The asterisk (*) indicates where the GNRHR gene is located on the chromosome. Figure 4 Functional studies of the wild-type, Gly99Glu mutant, and Gly99Glu-tailed mutant GnRH-R gene products. Vector is used as a negative control. (A) Competitive binding characteristics for Gly99Glu mutant and Gly99Glu-tailed mutant compared to wild type; (B) Inositol phosphate accumulation in COS-7 cells expressing wild-type GnRH-R, Gly99Glu mutant, and Gly99Glu-tailed mutant GnRH-R.
effects on GnRH-stimulated maximal IP response and GnRH potency (Fig. 4B) .
After the confirmation of the genetic diagnosis, the patient and his parents were counseled. Therapy with gonadotropins (purified FSH 75 UI and hCG 2500 UI 3 times/week) was prescribed to the patient which resulted in a progressive virilization and descent of the testes. Despite gonadotropin stimulation, spermatozoa were not observed in repeated semen analysis after 6 and 12 months of treatment. Hence, the dosage of FSH has been increased to 150 UI (3 times/week) and after 18 months semen analysis revealed severe oligozoospermia, allowing sperm cryopreservation. Afterward, the patient was shifted to testosterone therapy (injectable T undecanoate every 12 weeks), which is still ongoing.
Review of the effects of previously identified GNRHR mutations
Fifty-five ncHH-associated variants, distributed throughout the coding sequence and the exon/intron junctions of the GNRHR gene, were identified through both a literature search in PubMed and by using The Human Gene Mutation Database (HGMD â ) ( Table S4 ). The most affected domains are the TMDs in which reside 75% of all variants. GNRHR variants are usually identified as partial loss-of-function (pLOF) or complete loss-offunction (cLOF) mutations, based on their in vitro function. However, some pLOF variants have such severely decreased GnRH binding affinity that they cannot respond to physiological GnRH concentrations and are thus unlikely to be functional in vivo. Therefore, we have subclassified them as 'severe pLOF' variants (Table 2) . Functional tests are available for a total of 27 GNRHR variants (26 missense and one nonsense) of which three can be classified as pLOF, eight as severe pLOF and 16 as cLOF variants and the pGly99Glu variant shows severe pLOF (Table 2) .
Most ncHH-associated GNRHR mutations disrupt cell surface expression of the GnRH-R protein. In many cases of decreased expression, the mutated residue is part of the conserved intramolecular interaction networks that stabilize GPCR structures (Table 2) . Seven mutations decreased GnRH binding affinity, and most of them are located at the N-terminus, the extracellular end of TMD2 or ECL1 (Table 2) , close to the novel p.Gly99Glu mutation. A further four mutations decrease GnRHstimulated signaling, with much smaller effects on binding affinity, showing that they disrupt the receptor activation process or interaction with G proteins (Table 2) .
The in vivo functional effect of a given mutation can be defined only when the variant is in homozygosis. A homozygous genotype has been reported in 21 of 55 mutations. Based on a few clinical parameters, the severity of the in vivo effect can be divided into 'severe', 'moderate', and 'mild' (for further details, see footnotes of the Table S4 ). For a total of 11 homozygous variants with known phenotype, in vitro functional studies are available allowing us to define the capacity of in vitro studies to predict the in vivo effect. Five variants that are identified as cLOF result in three severe and two severe/moderate functional effects in vivo. On the other hand, the severe pLOF variants (n = 6) are associated with a more heterogeneous in vivo effects ranging from severe to moderate/mild.
We evaluated whether the three most frequently used in silico prediction tools (SIFT, PolyPhen-2, and MutationTaster) would predict the established functional effects of the 28 mutations (Table 2 ). For the 28 GNRHR variants (including p.Gly99Glu), the prediction tools were discordant with one another in 32% of cases (Table 2 ) and misclassified many of the known pathogenic mutations as benign or only possibly deleterious (Table 2 , Fig. 5 ). Of the cLOF mutations, 7% and 12.5% were predicted to be benign by SIFT and MutationTaster, while 20% and 12.5% were predicted to be only possibly deleterious by Poly-Phen2 and MutationTaster. All of the severe pLOF mutations were correctly identified by MutationTaster, but 22% were misclassified by SIFT and PolyPhen-2, which classified 11% as possibly deleterious. The highest percentages of misclassifications were observed for the pLOF variants (Fig. 5) .
DISCUSSION
ncHH is a genetically and phenotypically heterogeneous pathology. One of the most frequently mutated genes in ncHH is the GNRHR gene encoding the GnRH receptor (Boehm et al., 2015) . We report a case of a 20-year-old man with severe ncHH, in whom the diagnostic workup revealed partial empty sella and a novel homozygous p.Gly99Glu mutation in the GNRHR. We demonstrated the molecular origin and the pathogenic role of this novel homozygous variant through SNP array and in vitro functional analyses, respectively. We show that the patient inherited both copies of the mutant GNRHR from his mother, as a result of segmental iUPD in chromosome 4. The functional analysis revealed a right-shifted GnRH-stimulated signaling response, consistent with severely decreased GnRH binding affinity of the p.Gly99Glu GnRH-R. Our review of ncHH-associated GNRHR mutations ( Table 2, Table S4 ) shows that the patient's homozygous inheritance of this severe pLOF mutation fully accounts for his hypogonadism.
Discussing genetic aspects
A peculiar genetic aspect of this case is the type of transmission of the mutation. Molecular analysis in the parents revealed that the mother was heterozygous for p.Gly99Glu mutation of the GNRHR and the father was heterozygous for the p.Pro146Ser variant in the same gene, whereas the patient was homozygous for p.Gly99Glu mutation. The p.Pro146Ser variant was previously identified in two sisters with ncHH and in their mother, who had no signs of ncHH (Vagenakis et al., 2005) . Similarly, the father of our patient had normal puberty and no signs of hypogonadism suggesting that the phenotype of the two affected sisters is likely to be due to the presence of an additional mutation in another ncHH gene.
We have defined the maternal iUPD of chromosome 4 (matUPD4) as a genetic mechanism by which the mutation was present on both alleles. Specifically, the patient inherited both chromosome 4 homologues from the mother (no copy being inherited from the father) combined with only a single maternal allele in two regions, one of which contains the mutated GNRHR gene.
The population prevalence of UPD is 1 in 3500 (Robinson, 2000) , and more than 50 patients with recessive disorders due to iUPD have been reported in the literature (Engel, 2006; Yamazawa et al., 2010) . MatUPD4 has occurred in 12 patients affected by different diseases (Yang et al., 1999; Kuchinka et Table 2 Functional effects of GNRHR mutations. GnRH-R mutants that have been assessed in vitro are listed with the protein domain in which they are located. In silico predictions of the effects of mutations from three programs are compared in vitro measurements, which are classified and interpreted in terms of their effect on receptor function Papadimitriou et al., 2015) , but not described in ncHH (Fig. 6) . Among the MatUPD4 cases described so far, only four of these cases presented combined maternal hUPD/iUPD of chromosome 4, similar to our patient (Aminoff et al., 2012; Cottrell et al., 2012; Ding et al., 2012; Losekoot et al., 2012) . UPD is thought to be primarily caused by meiotic nondisjunction events, followed by one of several mechanisms previously described, including trisomy and monosomy rescue, gamete complementation, and post-fertilization errors (Kotzot & Utermann, 2005) . The mixed form of hUPD/iUPD on the same chromosome may have occurred due to recombination and non-disjunction during meiosis I, followed by post-zygotic Predictions are presented in the order Sift, Polyphen2, and MutationTaster, with B, tolerated/benign/polymorphism; P, possibly damaging/disease causing with p < 0.5; D, deleterious/damaging/disease causing; na, not available. b Although many studies have reported cell surface immunofluorescence of epitope-tagged mutant receptors, it has been found that stabilization of the mutant GnRH-R proteins (by appending a carboxy-terminal tail or incubating with membrane-permeable GnRH-R antagonists, called pharmacoperones) rescues mutant receptor function (Leaños-Miranda et al., 2002; Maya-N uñez et al., 2002) . This showed that fluorescence-based approaches overestimate mutant protein expression and more quantitative techniques, such as Western blot analysis or ligand binding (if affinity is not severely affected), provide more reliable assessments of mutant receptor expression (Meysing et al., 2004; Topaloglu et al., 2006) . c Functional classification is defined as complete loss of function (cLOF) when there is no measurable in vitro signaling (IP production or genetic reporter systems), partial loss of function (pLOF) when the maximal signaling response is at least 10% of wild-type GnRH-R signaling, and the EC 50 value for GnRH stimulation of signaling is increased less than fivefold. Severe pLOF is defined as maximal signaling response less 10% of wild-type GnRH-R or GnRH EC 50 value increased greater than fivefold. The functional effects of individual mutations were assessed from interpretation of ligand binding and various signaling assays combined with 'rescue' of mutant receptor function using pharmacoperones or additional mutagenesis. trisomy rescue or gamete complementation during fertilization. In the case of our ncHH patient, it is known that the UPD event was maternal in origin and that the patient's mother was of a relatively advanced maternal age (35 years) at the time of his birth. Thus, the most likely mechanism of UPD formation is a trisomy rescue, initiated by the occurrence of maternal nondisjunctions during meiosis.
Both hUPD and iUPD can result in imprinting disorders if they involve imprinted genes, which are characterized by monoallelic expression in a parent-of-origin-specific manner. To date, approximately 100 imprinted genes, implicated mainly in the control of fetal and postnatal growth, are known (Eggermann et al., 2017) . As our patient has no paternal contribution from the whole of chromosome 4, we sought to explore the presence of maternally imprinted genes on chromosome 4. The NAP1L5 gene, mapping to the long arm of chromosome 4 (4q22.1), has monoallelic paternal expression (Smith et al., 2003; Wood et al., 2007) . It belongs to the class of nucleosome assemble protein lacking nuclear localization signal sequence and it is localized to the cytoplasm (Harada et al., 2002) . In mice, the ortholog of this gene is on chromosome 6 and is located close to a cluster of imprinted genes. The removal of Nap1l5 together with the cluster causes fetal growth retardation (Beechey, 2004) . Up to now, 10 cases of maternal UPD4 including also the NAP1L5 locus have been reported (Yang et al., 1999; Kuchinka et al., 2001; Spena et al., 2004; Middleton et al., 2006; Aminoff et al., 2012; Cottrell et al., 2012; Ding et al., 2012; Losekoot et al., 2012; Palumbo et al., 2015; Papadimitriou et al., 2015) . Information on the patient's height was given only by four papers: Three patients had short stature (Yang et al., 1999; Kuchinka et al., 2001; Losekoot et al., 2012) , while one presented the target stature (Palumbo et al., 2015) . In two papers, the authors emphasize the absence of dysmorphic features or developmental abnormalities (Ding et al., 2012; Palumbo et al., 2015) . Our proband's height (165 cm) corresponds to 10th percentile according to the national derived growth charts and he does not show any dysmorphic features or congenital malformations. It remains therefore an open question whether the lack of NAP1L5 gene expression in humans may cause short stature.
How mutations disrupt GnRH-R function and the effect of p.Gly99Glu
The attribution of a pathogenic role to a novel mutation is a challenging clinical task. It is especially true for variants in genes coding for receptors, as the consequence of these mutations may present a wide range of functional effects. Although a number of in silico predictive tools are available, their predictions are often discordant between different tools and do not allow clearcut conclusions (Table 2, Fig. 5 ). Due to the imprecision of these tests, functional analyses remain necessary to define the Figure 5 Comparison between in vitro and in silico data provided by three predictive tools: Panel (A) (SIFT): B, tolerated; D, damaging. Panel (B) (PolyPhen-2): B, benign; P, possibly damaging; D, probably damaging. Panel (C) (Mutation Taster): B, polymorphism; P, disease causing with probability value <0.5; D, disease causing.
diagnosis, especially when non-genetic factors (such as empty sella) may also contribute to the phenotype.
Disease-associated mutations that disrupt GPCR function have been grouped into classes based on how they disrupt receptor function. Class I mutations disrupt protein biosynthesis, typically via frameshift, nonsense, or start codon mutations, of which seven have been described in the GNRHR (Table S4) . Class II mutations disrupt folding and transport of receptor proteins during biosynthesis, resulting in decreased cell surface expression, whereas class III mutations preserve expression, but disrupt ligand binding and class IV mutations preserve ligand binding, but disrupt receptor activation or G protein interaction (Tao & Conn, 2014) . As is the case for disease-causing mutations of other GPCRs (Tao & Conn, 2014) , most of the ncHH-associated GNRHR mutations that have been characterized in vitro decrease cell surface expression of the mutant GnRH-R protein (Table 2) . In many cases, the mutated residues in the GnRH-R are equivalent to residues that form conserved intramolecular (interhelical) interactions that define and stabilize the conserved GPCR structural fold (Table 2) (Venkatakrishnan et al., 2013; Cvicek et al., 2016; Flanagan & Manilall, 2017) , suggesting that disruption of their role in receptor folding may cause misfolding that decreases protein expression. Of the four class IV mutations of GNRHR, three involve residues that have previously been implicated in conserved GPCR activation pathways ( Table 2 ), suggesting that the mutations disrupt intramolecular interactions that mediate activation of the GnRH-R (Flanagan & Manilall, 2017) . The prevalence of mutations that disrupt intramolecular interactions that are conserved in GPCRs suggests that an in silico tool based on GPCR structures may better predict the effects of disease-associated mutations in GNRHR and other GPCR genes.
Of the class III GNRHR mutations, four, including the p.Gly99-Glu mutation, are located at the TMD2-ECL1 interface of the GnRH-R protein, where artificially created GnRH-R mutants have identified three additional residues that are also important for ligand binding (Flanagan & Manilall, 2017) . Amino acid residues in the TMD2-ECL1 region of the GnRH-R may directly contact GnRH, as has been proposed for the Asp98 and Asn102 residues (Flanagan & Manilall, 2017) , or they may form intramolecular interactions that stabilize the shape of the ligand binding pocket. Mutations of these residues may disrupt a direct contact with the ligand, disrupt intramolecular interactions that configure the ligand-binding pocket or sterically inhibit direct contact of the ligand with one or more other residues.
The p.Gly99Glu mutation is immediately adjacent to the Asp98 residue which contributes to high-affinity agonist binding both via direct interactions with the ligand and indirectly, via intramolecular interactions that contribute to the formation of the binding pocket (Flanagan et al., 2000 ; Flanagan & Figure 6 Schematic representation of chromosome 4 and related cases of maternal uniparental disomy, including the proband in the current paper. Dashed lines represent maternal isodisomy, continuous lines represent maternal heterodisomy, and double continuous lines indicate a biparental inheritance of chromosome 4.
98 Andrology, 2019, 7, 88-101 Manilall, 2017). The GnRH-stimulated IP production in cells transfected with the p.Gly99Glu mutant shows that the mutant was well expressed and that the lack of measurable ligand binding was due to decreased affinity. The increased EC 50 values, which are considerably higher than the IC 50 for GnRH binding to the wild-type receptor, show that the mutation severely decreases GnRH binding affinity (by about two orders of magnitude). The Gly99 residue is very small, having no sidechain, whereas the Glu side-chain is large and negatively charged. Based on this, Gly99 is likely not to have a direct role in ligand binding, but substituting it with Glu may sterically inhibit access of the ligand (to Asp98) and may distort the ligand-binding pocket. This likely accounts for the observed decreases in GnRH potency and binding affinity at the p.Gly99-Glu mutant GnRH-R.
Links between mutations and clinical phenotypes
The clinical consequence of different GNRHR mutations is highly variable, although some general rules may apply. Patients homozygous for cLOF mutations usually have complete ncHH, that is, absent puberty, undetectable serum basal LH and FSH levels with cryptorchidism, and micropenis in males and absent breast development in females. Similarly, severe pLOF mutations also lead to severe ncHH or rarely to moderate form (amenorrhea and breast Tanner Stage ≥1 in the females; absence of puberty by age of 18 without cryptorchidism or micropenis in the males). On the other hand, as might be expected, homozygous pLOF mutations are associated with a mild phenotypic form of ncHH, that is, some virilization, gynecomastia, and a testicular volume above 4 mL or even close to normal in men and oligomenorrhea with partial breast development in the female patients. The exact genotype/phenotype correlation of different mutations is complicated by the fact that the large majority of patients are compound heterozygotes, hence the phenotype derives from a combination of two or more different mutations with different functional effects. However, our comprehensive analysis of the 55 mutations seems to suggest that the presence of a cLOF mutation in compound heterozygosis is determinant for the phenotype, that is, it is sufficient to lead to severe ncHH phenotype in the majority of cases.
Linking the disruption of receptor function in the p.Gly99Glu GnRH-R to the patient's phenotype Our patient with severe ncHH was found to have a novel homozygous p.Gly99Glu GNRHR mutation. The variant was predicted to be deleterious by three different tools (SIFT, PolyPhen-2, and MutationTaster). Our functional studies showed that the p.Gly99Glu GnRH-Rs were expressed on the cell surface, but GnRH potency was severely decreased (EC 50 , 899.3 nM), confirming the in silico predictions. It is likely that this severe pLOF GnRH-R mutant cannot bind and respond to endogenous GnRH concentrations in the patient. Supporting this, our analysis of ncHH patient phenotypes shows that other severe pLOF mutations p.Arg139Cys, p.Cys200Tyr, p.Arg262Gln, and p.Tyr284Cys are associated with severe disease with the exception of p.Gln106Arg causing mild phenotype in homozygous patients (Table S4) . Thus, it is likely that the homozygous p.Gly99Glu GNRHR mutation fully explains our patient's severe ncHH.
It has been proposed that orally active pharmacoperones, similar to those used for in vitro rescue experiments, can be used to treat ncHH patients (Tao & Conn, 2014) . Supporting this, a pharmacoperone restored sex hormone production in transgenic mice homozygous for the cLOF p.Glu90Lys mutant GnRH-R and a pharmacoperone decreased symptoms of nephrogenic diabetes insipidus in patients with class II AVPR2 mutations (Tao & Conn, 2014) . The clinical development of elagolix and other orally active small molecule GnRH-R antagonists, for other applications (Goenka et al., 2017) , provides potential novel therapy for ncHH patients with class II (disrupted cell membrane trafficking) GnRH-R mutants that can interact with endogenous GnRH, once expressed at the cell membrane. However, patients with class III or IV GnRH-R mutants, such as our patient's variant, which cannot respond to endogenous GnRH concentrations, are less likely to benefit from these new drugs.
In conclusion, this is the first ncHH patient carrying a novel causative missense mutation of the GNRHR (p.Gly99Glu) with proven 'severe pLOF' due to maternal hUPD/iUPD of chromosome 4. Our literature review shows that commonly used in silico tools are poor predictors of the function of ncHH-associated GNRHR variants mainly because they are not based on information concerning the disruption of conserved GPCR structures. Considering whether mutated residues are part of conserved GPCR structures helps to identify relatively common class II mutations, which may one day be amenable to treatment with orally active GnRH antagonists. Therefore, functional studies remain an essential tool both for diagnostic and potential therapeutic purposes.
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